The Industry’s Preeminent Event on Novel Drug Targets

SEPTEMBER 24 - 25
- Targeting Epigenetic Readers
- Targeting Histone Methyltransferases
- GPCR-Based Drug Discovery
- Functional Genomics Screening Strategies - Part One
- Novel Strategies for Kinase Inhibitors
- Antibodies Against Membrane Protein Targets - Part One

SEPTEMBER 25 – 26
- Next-Generation Histone Deacetylase Inhibitors
- Targeting Histone Demethylases
- GPCR-Targeted Therapeutics
- Functional Genomics Screening Strategies - Part Two
- Cardio-Metabolic Drug Targets
- Antibodies Against Membrane Protein Targets - Part Two

PLENARY KEYNOTE SPEAKERS

Towards a Patient-Based Drug Discovery
Stuart L. Schreiber, Ph.D., Director, Chemical Biology, Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical Institute Investigator; Morris Loeb Professor of Chemistry and Chemical Biology, Harvard University

Enteroendocrine Drug Discovery for Treatment of Metabolic Diseases
Paul L. Feldman, Ph.D., Senior Vice President, GlaxoSmithKline

EVENT FEATURES
- 12 Conferences
- 150+ Scientific Presentations
- 10 Interactive Short Courses
- 35+ Breakout Discussion Groups
- Exhibit Hall, Poster Viewings & Networking Opportunities

PREMIER SPONSORS

CELECTA
Discovery is Yours.

Promega
<table>
<thead>
<tr>
<th><strong>Monday</strong></th>
<th><strong>September 23</strong></th>
<th><strong>Conference Short Courses</strong>*</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 3:00 PM</td>
<td>SC1: New Class of Kinase Inhibitors: Covalent Modifiers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC2: Practical Aspects of Structure-Based Drug Discovery with GPCRs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC3: Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery</td>
<td></td>
</tr>
<tr>
<td>3:30 - 6:30 PM</td>
<td>SC4: Allosteric Modulators of GPCRs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC5: Advancing Tools and Technologies for Fragment-Based Design</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC6: Setting Up Effective RNAi Screens: Getting From Design to Data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC7: Production and Presentation of Integral Membrane Proteins for Antibody Discovery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC8: Characterization and Quantification of Histone Modifications</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tuesday</strong></th>
<th><strong>September 24</strong></th>
<th><strong>Conference Short Courses</strong>*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Targeting Epigenetic Readers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting Histone Demethylases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GPCR-Based Drug Discovery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Functional Genomics Screening Strategies – Part One</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel Strategies for Kinase Inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antibodies Against Membrane Protein Targets – Part One</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Wednesday AM</strong></th>
<th><strong>September 25</strong></th>
<th><strong>Conference Short Courses</strong>*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Targeting Epigenetic Readers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting Histone Methytransferases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GPCR-Based Drug Discovery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Functional Genomics Screening Strategies – Part One</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel Strategies for Kinase Inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antibodies Against Membrane Protein Targets – Part One</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Wednesday PM</strong></th>
<th><strong>September 25</strong></th>
<th><strong>Conference Short Courses</strong>*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Next-Generation Histone Deacetylase Inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting Histone Demethylases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GPCR-Targeted Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Functional Genomics Screening Strategies – Part Two</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardio-Metabolic Drug Targets</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antibodies Against Membrane Protein Targets – Part Two</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Thursday</strong></th>
<th><strong>September 26</strong></th>
<th><strong>Conference Short Courses</strong>*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Next-Generation Histone Deacetylase Inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting Histone Demethylases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GPCR-Targeted Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Functional Genomics Screening Strategies – Part Two</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardio-Metabolic Drug Targets</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antibodies Against Membrane Protein Targets – Part Two</td>
<td></td>
</tr>
</tbody>
</table>

*Separate Registration Required.

Cambridge Healthtech Institute will host its **11th Annual Discovery on Target** meeting showcasing current and emerging “hot” targets for the pharmaceutical industry from September 24-26, 2013 in Boston, MA. Spanning three days, the meeting attracts 700+ attendees, composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. The meeting is comprised of 12 meeting tracks which include Targeting Epigenetic Readers; Targeting Histone Methyltransferases; Next-Generation Histone Deacetylase Inhibitors; Targeting Histone Demethylases; GPCR-Based Drug Discovery; GPCR-Targeted Therapeutics; Functional Genomics Screening Strategies; Novel Strategies for Kinase Inhibitors; Antibodies against Membrane Protein Targets, and Cardio-Metabolic Drug Targets. The 2013 event will offer 150+ scientific presentations across these 12 conference tracks and 10 pre-conference short courses, 30+ interactive breakout discussion groups, an exhibit hall of 30+ companies, and dedicated poster viewing and networking sessions. The 11th Annual Discovery on Target assembles an impressive group of 175+ distinguished speakers who look forward to sharing their knowledge, best practices, and expertise with all attendees.
Towards a Patient-Based Drug Discovery
Stuart L. Schreiber, Ph.D., Director, Chemical Biology, Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical Institute Investigator; Morris Loeb Professor of Chemistry and Chemical Biology, Harvard University

Small-molecule drugs were originally discovered using compound-based drug discovery: opportunistic discovery of a biologically active compound, often a natural product (e.g., penicillin) followed by a search for a disease that might be treated with the compound. This remains a common approach to modern drug discovery (e.g., rapamycin and analogs for use as antifungal agents; immune suppression agents; anti-cancer agents; possibly others in the future). The advent of recombinant DNA accelerated a second approach – target-based drug discovery – where the therapeutic target is selected and subjected to methods that yield candidate drugs (mechanism-based design; structure-based design; screening). But this approach has its shortcomings – 97% of drug candidates that enter into clinical investigation eventually fail, many due to unanticipated toxicity and many others due to a lack of efficacy despite successful modulation of the target. Selecting therapeutic targets based on information derived from surrogates of patients has proved challenging. Advances in human biology, including human genetics and physiology, and in small-molecule science, including chemistry and chemical biology, are now accelerating a third approach – patient-based drug discovery. This lecture will present examples that aim to use: 1) information from heritable or somatic human genetics in human disease, for example, in Crohn’s Disease and cancer, 2) advances in diversity-oriented synthetic chemistry and chemical biology to accelerate the discovery of safe and effective small-molecule therapeutics, and 3) an understanding of the relationship of human genetic variation to drug efficacy.

Enteroendocrine Drug Discovery for Treatment of Metabolic Diseases
Paul L. Feldman, Ph.D., Senior Vice President, GlaxoSmithKline

The Enteroendocrine Discovery Performance Unit at GlaxoSmithKline is focused on discovering and developing medicines that mimic the efficacy of Roux-en-Y gastric bypass surgery to treat metabolic diseases. Our strategy emanates from the findings that there are significant metabolic benefits to obese and obese diabetic patients that undergo Roux-en-Y gastric bypass surgery. In general, these patients experience ~30% weight loss while >80% of obese diabetics who undergo this surgery have complete “remission” of diabetes. Our strategy is focused on three areas: 1) enteroendocrine science: discovery efforts focused on targets expressed on the luminal surface of the GI tract and peptides secreted from the GI tract or other peptides known to have metabolic effects, 2) combination therapies: by first intent progress combinations of assets that work synergistically to manifest significant, differentiated metabolic efficacy, and 3) assets that minimize safety risks: peptide based therapeutics and GI luminally restricted small molecule therapeutics. In this presentation, I will describe the strategy our Unit has taken to discover novel combination peptide-based and GI luminally restricted small molecule therapeutics.
SPONSORSHIP, EXHIBIT, AND LEAD GENERATION

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post-show delegate lists. Customizable sponsorship packages allow you to achieve your objectives before, during, and long after the event. Signing on early will allow you to maximize your exposure to hard-to-reach decision makers!

Agenda Presentations
Showcase your solutions to a guaranteed, highly-targeted audience. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding and access to cooperative marketing efforts by CHI.

Luncheon Presentations
Opportunity includes a 30-minute podium presentation. Boxed lunches are delivered directly into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite
Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor’s objectives (i.e. purely social, focus group, reception style or plated dinner with specific conversation focus).

Exhibit
Exhibitors will enjoy facilitated networking opportunities with 700+ high-level delegates, making it the perfect opportunity to speak face-to-face with prospective clients and showcase your latest product, service, or solution.

*Additional branding & promotional opportunities are available!

Looking for additional ways to drive leads to your sales team? CHI can help through:

Custom Lead Generation Programs:
- Targeted campaign promotion to unparalleled database of 800,000+ individuals in the life sciences
- Experienced marketing team promotes campaign, increasing awareness and leads

Live Webinars:
- Assistance in procuring speakers
- Experienced moderators
- Dedicated operations team to coordinate all efforts

Whitepapers:
- Industry recognized authors, with vast editorial experience, available to help write your whitepaper

CHI also offers market surveys, podcasts and more!

For additional information, please contact:
Jon Stroup – Business Development Manager
781-972-5483 | jstroup@healthech.com

2012 Attendee Demographics

Company Type

- Pharma 25%
- Biotech/Comm 34%
- CRO/Hospital 5%
- Other 4%
- Academic 29%
- Government 3%

Company Title

- Other 6%
- Executive 10%
- Professor 22%
- Director 11%
- Manager 7%
- Scientist/Technologist 44%

Geographic Location

- East Coast 49%
- West Coast 12%
- Mid West 11%
- Other 3%
- Asia 9%
- USA 72%

*Talks were interesting and informative. Time flew by.*
Dept. of Pharmacology, SUNY Upstate Medical University
HOTEL & TRAVEL INFORMATION

Conference Hotel: Westin Boston Waterfront
425 Summer St.
Boston, MA 02210
T: 617-532-4600

Discounted Room Rate: $269 s/d
Discounted Room Rate Cut-off Date: August 26, 2013

Please visit our conference website or call the hotel directly to reserve your sleeping accommodations. You will need to identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate with the host hotel. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space and rate-availability basis. Rooms are limited, so please book early.

TOP REASONS TO STAY AT THE WESTIN BOSTON WATERFRONT HOTEL:
• Take advantage of the $269 group rate!
• No Commute, since meeting takes place at hotel
• Complimentary wireless internet access in guest rooms
• Lots of new restaurants within walking distances. Waterfront is the up and coming area of Boston!

Flight Discounts:
Special discount rentals have been established with American Airlines for this conference.
• Call American Airlines 1-800-433-1790 use Conference code 2593BF.
• Go to www.aa.com/group enter Conference code 2593BF in promotion discount box.
• Contact our designated travel agent, Rona Meizler, at 617-559-3735 or rona.meizler@protravel.com

Car Rental Discounts:
Special discount rentals have been established with Hertz for this conference.
• Call Hertz 1-800-654-3131 use our Hertz Convention Number (CV): 04KL0003
• Go to www.hertz.com use our Hertz Convention Number (CV): 04KL0003

“Friendly, informative, ground-breaking with a free, no-holds-barred discussion - the very best of scientific exchange!”
CEO, GenoMed, Inc.
SC1: New Class of Kinase Inhibitors: Covalent Modifiers
Interest in covalent kinase inhibitors as potential drug candidates is steadily increasing and there is a growing body of data showing both efficacy and safety in patients. Covalent inhibitors offer a means of obtaining optimal target engagement with excellent selectivity and a prolonged duration of action. This workshop will cover practical and theoretical considerations for designing selective covalent kinase inhibitors, as well as considerations for testing schemes to examine on- and off-target activities.
Instructors:
Alan Corin, Ph.D., Senior Director, Biochemistry and Molecular Pharmacology, Celgene Avilomics Research
Eric Schwartz, Ph.D., Senior Director, Chemistry, Celgene Avilomics Research

SC2: Practical Aspects of Structure-Based Drug Discovery with GPCRs
This course will explore the changes in rational drug design approaches for GPCRs in light of the new structural knowledge now available from the many new GPCR crystal structures. Questions such as quality of crystal data, expected throughput and turnaround times and impact on modeling activities will be explored.
Instructor:
Michael Hansen, Ph.D., Director, Structural Biology, Receptos

SC3: Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery
An increasing amount of chemically tractable compounds modulating various epigenetic targets are now in pre-clinical and clinical development. However, obtaining potent, highly-selective and cell-active inhibitors, requires skillful utilization of varied assays and screening methods such as high-throughput screening (HTS), focused screening, knowledge-based and fragment-based approaches, to efficiently navigate lead discovery of epigenetic targets. This workshop is designed as a tutorial by discovery leaders to discuss tools and techniques, application specific methods, and best practices for the development of chemically tractable epigenetic inhibitors.
Instructors:
David Sheppard, Ph.D., Director, Computational Chemistry, BioFocus
Zhaoxui Sunny Zhou, Ph.D., Faculty Fellow, Barnett Institute of Chemical and Biological Analysis; Associate Professor, Department of Chemistry and Chemical Biology, Northeastern University
Alan P. Graves, Ph.D., Investigator, Platform Technology and Sciences, GlaxoSmithKline

SC4: Allosteric Modulators of GPCRs
Allosteric modulators represent a novel paradigm to therapeutically target G-protein-coupled receptors (GPCRs). However, their identification and characterization using standard functional assays remain elusive due to the ‘context-dependent phenomena’. This course will discuss important aspects of hit identification and validation of allosteric modulators in GPCR research activity.
Instructors:
Corey Hopkins, Ph.D., Research Assistant Professor, Pharmacology, Vanderbilt University
Debra Kendall, Ph.D., Distinguished Professor & Department Head, Pharmaceutical Sciences, University of Connecticut
Stephan Scharin, Ph.D., Head, Research, Domain Therapeutics SA

SC5: Advancing Tools and Technologies for Fragment-Based Design
This course aims to introduce the fundamentals of Fragment-based Lead Discovery (FBLD) to attendees. The first section will focus on the concepts of using fragments for hit generation. Special emphasis will be placed on practical pitfalls and the many ways to advance fragments to leads and drugs. The second part of the course will discuss the variety of fragment screening methods and when they are best applied. The composition of fragment libraries will also be discussed in detail. The attendees should come away from this course with a solid understanding of what FBLD is and how to apply it.
Instructors:
Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.
Edward R. Zartler, Ph.D., President & CSO, Quantum Tessa Consulting

SC6: Setting Up Effective RNAi Screens: Getting From Design to Data
The course is designed to provide in-depth information on how to go about setting up RNAi screening experiments and how to design assays for getting optimal results. The challenges working with siRNAs and shRNAs and the delivery reagents needed to get them into the appropriate cells and tissues will be discussed. The instructors will also provide their insight on best practices for the execution of experiments and interpretation of results when dealing with complex biology and informatics.
Instructors:
Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility, Harvard Medical School
Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health
John Doench, Ph.D., Research Scientist, Broad Institute of Harvard and MIT
Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Institutes of Health

SC7: Production and Presentation of Integral Membrane Proteins for Antibody Discovery
Small molecule pharmaceuticals can exhibit remarkable target specificity. Nevertheless, the exquisite selectivity towards the desired subtype of an ion channel or GPCR is often elusive, resulting in undesirable effects on closely related variants. Antibodies hold promise of even greater specificity, and are proven to be effective therapeutics targeting certain membrane proteins. Yet none of the current targets for approved antibodies is either a GPCR or an ion channel. A main reason for this is the difficulty involved in the effective presentation of integral membrane proteins for antibody generation-selection. This workshop surveys the latest methods and insights to generate useful antibodies to integral membrane proteins, and to favor the desired binding interactions for the therapeutic mechanism or diagnostic purpose.
Instructor: David Bramhill, Ph.D., Principal, Bramhill Biological Consulting, LLC

SC8: Characterization and Quantification of Histone Modifications
Until recently, standardized high-throughput methods for characterizing and quantifying post-translational histone modifications have been challenging. Now, with the application of advanced methods utilizing modification-specific antibodies and high resolution mass spectrometry, various strategies have been developed for precise in vivo monitoring and profiling of histones, their variants, reader proteins, the combinatorial histone code, and the overarching chromatin landscape in multiple cellular states. This workshop is designed to provide a tutorial on utilizing what is becoming the gold standard for histone post-translational modification analysis.
Instructors:
Alan Tackett, Ph.D., Associate Professor, Director UAMS Proteomics Facility, University of Arkansas for Medical Sciences
Sean Taverna, Ph.D., Assistant professor, Pharmacology & Molecular Sciences, IBBS Center for Epigenetics, Johns Hopkins University School of Medicine
Yingming Zhao, Ph.D., Professor, The Ben May Department for Cancer Research, University of Chicago

“Very fruitful meeting with excellent basic research and clinical applications.”
CEO Metabolys, Inc.
SC9: Setting Up Effective Functional Screens Using 3D Cell Cultures
The course is designed to provide in-depth information on how to go about setting up low and high-throughput screening experiments using 3D cell cultures. The challenges working with 3D cell cultures, from experimental design to data analysis will be discussed. The instructors will also share their experiences on how they tested and evaluated various cell culture reagents and growth matrices, what worked and what didn’t and what you need to consider when setting up similar screens in your lab.
Instructors:
Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Lesley Mathews, Ph.D., Research Scientist, Biomolecular Screening and Profiling/Probe Development Group, National Center for Advancing Translational Sciences, NIH
Additional Instructors to be Announced

SC10: Tools for Epigenetic Biomarker Discovery
Evaluation of Potential Ex Vivo Biomarkers and Molecular Imaging to Determine Early Pharmacodynamic Efficacy of HDAC Inhibitors
Pamela Munster, M.D., Professor of Medicine, Director of Early Phase Clinical Trials’ Program and Associate Director of Investigational Therapeutics, University of California, San Francisco
Development of Methods to Assess Epigenetic Markers of Phenotypic Heterogeneity Using Physiologically Relevant Cell Culture Models
Sophie Lelièvre, D.V.M., LL.M., Ph.D., Associate Professor, Department of Basic Medical Sciences; Associate Director, Discovery Groups, NCI-Designated Purdue Center for Cancer Research, Purdue University
An Integrated PTM-Technology Platform for Biomarker Discovery and Hard-to-make Reagents
Jack Zhongyi Cheng, Ph.D., CEO, PTM Biolabs, Inc

“Thank you for this well organized meeting.”
Dept. of Biochem & Mol Biol, Tel Aviv University

Sponsored by

*Separate Registration Required for Short Courses
TUESDAY, SEPTEMBER 24

7:00 am Registration and Morning Coffee

FEATURED SESSION: LEADERS IN EPIGENETIC DRUG DISCOVERY

8:10 Chairperson’s Opening Remarks

8:15 Drugging the Epigenome
Cheryl H. Arrowsmith, Ph.D., Chief Scientist, Structural Genomics Consortium; Professor, Medical Biophysics; Canada Research Chair, Structural Proteomics, University of Toronto

9:00 Drugging the Epigenome in Cancer
Peter J. Tunamoto, Ph.D., Head, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals

9:45 Monitoring inhibition of Bromodomain Protein
Gerald V. Denis, Ph.D., Associate Professor, Cancer Research Center, Department of Medicine, Boston Medical School; Assistant Professor, Pathology, Brigham and Women’s Hospital

10:15 Suggested Event Package
- September 23: Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery Short Course 3
- September 24: Characterization and Quantification of Histone Modifications Short Course 8
- September 24-25: Targeting Epigenetic Readers Conference
- September 25-26: Next-Generation Histone Deacetylase Inhibitors Conference

10:45 Targeting Bromodomains in NUT Midline Carcinoma
Christopher A. French, M.D., Assistant Professor, Department of Pathology, Harvard Medical School; Assistant Professor, Pathology, Brigham and Women’s Hospital

11:15 Suggested Presentation (Opportunity Available)

11:45 CHD5 and H3: A Must-Read for Tumor Suppression
Alee A. Mills, Ph.D., Professor & Team Leader, Cold Spring Harbor Laboratory

12:15 pm Talk Title to be Announced (Work Currently Undisclosed)
John Trzudek, Ph.D., MBA, Principal Scientist, Biotherapeutics, External Chemistry Innovation, Pfizer

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

PROGRESS TOWARDS NOVEL CHEMICAL READER ANTAGONISTS

2:15 Chairperson’s Opening Remarks

2:20 From Epigenetic Mechanism to Targeted Therapy
Ming-Ming Zhou, Ph.D., Harold and Golden Lampert Professor and Chairman, Department of Structural & Chemical Biology; Co-Director, ExperimentalTherapeutics Institute, Icahn School of Medicine at Mount Sinai

2:50 Promoting illiteracy: Inhibition of Methyl-Lysine Readers by Small Molecule Chemical Probes
Lindsey Ingeman James, Ph.D., Research Assistant Professor, Center for Integrative Chemical Biology & Drug Discovery Division of Chemical Biology and Medicinal Chemistry Eshelman School of Pharmacy; Visiting Scientist, Chemical Biology, GlaxoSmithKline, Research Triangle Park

3:20 Targeting Selective Inhibition of BET Proteins by Context Specific Engagement of Tandem Bromodomains with Coferons
Lee Arnold, Ph.D., Vice President & CSO, Coferon Inc.

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Disrupting the Reader
John M. Denu, Ph.D., Director, Epigenetics Theme, Wisconsin Institute for Discovery; Professor, Biomolecular Chemistry, School of Medicine and Public Health, University of Wisconsin

5:00 Histone Binding Mechanisms and Specificities of PHD Fingers
Tatiana Kutateladze, Ph.D., Associate Professor, Department of Pharmacology, Anschutz Medical Campus, University of Colorado

5:30 Interactive Breakout Discussion Groups

6:30 Welcome Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

WEDNESDAY, SEPTEMBER 25

7:30 am Registration and Morning Coffee

THERAPEUTIC APPLICATIONS OF INHIBITING BET BROMODOMAINS

8:00 Chairperson’s Opening Remarks

8:05 Targeting MYCN with BET Bromodomain Inhibitors
Kimberly Stegmaier, M.D., Associate Professor, Department of Pediatrics, Harvard Medical School; Independent Investigator, Pediatric Oncology, Dana-Farber Cancer Institute; Co-Director, Pediatric Hematologic Malignancy, Boston Children’s Hospital & DFCI; Associate Member, Broad Institute of Harvard and MIT

8:35 Bromodomain Inhibition as a Novel Therapeutic Treatment for Pulmonary Fibrosis
David C. Budd, Ph.D., Honorary Lecturer, Department of Inflammation, Center for Rheumatology & Connective Tissue Diseases, University College London Medical School

9:05 BET Proteins as Critical Links between Chronic Inflammation, Insulin-Resistant Obesity and Certain Cancers
Gerald V. Denis, Ph.D., Associate Professor, Cancer Research Center, Department of Pharmacology & Medicine, Boston University School of Medicine

9:35 Monitoring Inhibition of Bromodomain Protein Interactions with Chromatin in Living Cells Using BRET
Danette L. Daniels, Ph.D., Group Leader, Functional Proteomics, Promega Corporation

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 Mechanisms of BET Bromodomain Inhibition in the Control of Gene Expression
Robert J. Sims III, Ph.D., Senior Director of Biology, Constellation Pharmaceuticals, Inc.

11:20 Identification of Potent, BET Bromodomain Inhibitors for Treatment of Cancers
Hosahalli Subramanya, Ph.D., Senior Vice President, Structural Biology & Lead Generation, Aurigene Discovery Technologies, Ltd.

11:50 Lunch on Your Own

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Close of Conference
SUGGESTED EVENT PACKAGE

September 23: Characterization and Quantification of Histone Modifications Short Course 8
September 24-25: Targeting Epigenetic Readers Conference
September 25: Tools for Epigenetic Biomarker Discovery Dinner Short Course 10
September 25-26: Next-Generation Histone Deacetylase Inhibitors Conference

WEDNESDAY, SEPTEMBER 25

11:50 am Registration

DESIGNING THE IDEAL INHIBITOR

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Chairperson’s Opening Remarks

4:00 FEATURED PRESENTATION: Targeting Lysine Acetylation in Human Disease
James E. Bradner, M.D., Assistant Professor, Department of Medicine, Harvard Medical School and Investigator, Department of Medical Oncology, Dana-Farber Cancer Institute

4:30 Selective Bioluminescent HDAC Assays for Cell-Based Drug Development
Andrew L. Niles, Senior Research Scientist, Promega Corporation

5:00 Sirtuins: Aging, Diseases and Circadian Control
Leonard P. Guarente, Ph.D., Novartis Professor of Biology, Harvard University

5:30 Chemogenomic Approaches to Spatiotemporal Regulation of HDAC Activity
Ralph Mazitschek, Ph.D., Assistant Professor, Center for Systems Biology, Chemical Biology Platform, Massachusetts General Hospital

6:00 Novel Lysine Acylation Pathways and Acetylation-Independent Mechanisms of HDACs
Yingming Zhao, Ph.D., Professor, The Ben May Department for Cancer Research, University of Chicago

6:30 Close of Day

THURSDAY, SEPTEMBER 26

7:30 am Registration

HDACi FOR CARDIOVASCULAR INDICATIONS

8:00 Breakfast Interactive Breakout Discussion Groups

9:05 Chairperson’s Opening Remarks

9:10 HDAC Inhibitors for the Treatment of Pathological Muscle Remodeling
Timothy A. McKinsey, Ph.D., Associate Professor and Associate Division Head for Translational Research, Department of Medicine, Division of Cardiology, University of Colorado Denver

9:40 HDAC Inhibition to Target Heart Disease
Joseph Hill, M.D., Ph.D., Professor, Internal Medicine and Molecular Biology; Chief of Cardiology, University of Texas Southwestern Medical Center; Director, Harry S. Moss Heart Center

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:55 HDAC Inhibition and Cardiac Protection
Ting Zhao, M.D., Associate Professor, Department of Surgery, Roger Williams Medical Center, Boston University Medical School

HDACi FOR CNS INDICATIONS

11:25 HDACi in the Treatment of Muscular Dystrophies: Targeting Cellular and Molecular Networks that Control Muscle Repair
Pur Pier Lorenzo, M.D., Ph.D., IRCCS Fondazione Santa Lucia, Pharmacology and Epigenetics, Rome, Italy; Associate Professor, Sanford-Burnham Institute for Medical Research

11:55 Regulation of Excitatory and Inhibitory Synaptic Functions by HDAC2
Qiang Zhou, Ph.D., Scientist, Department of Neuroscience, Genentech Inc.

12:25 pm Sponsored Presentation (Opportunity Available)
12:55 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

HDACi FOR TARGETING IMMUNE AND METABOLIC DISORDERS

2:25 Chairperson’s Opening Remarks

2:30 Mechanisms By Which the HDAC3 Inhibitor BRD3308 Reduces Insulin Resistance in vivo
Gerald Shulman, M.D., Ph.D., Professor of Internal Medicine & Cellular and Molecular Physiology, Yale University; Investigator, Howard Hughes Medical Institute

3:00 Inhibition of HDAC3 Protects Beta-Cell Function
Bridget K. Wagner, Ph.D., Director, Pancreatic Cell Biology, Chemical Biology Program, The Broad Institute of MIT and Harvard

3:30 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Design of Class I Isoform Selective Inhibitors for Use in Metabolic Indications
Edward Holson Ph.D., Director, Medicinal Chemistry, Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard

4:30 HDAC6 and Immune Sexual Dimorphism: New Approaches to Autoimmunity
Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Chief of Transplant Immunology, Children's Hospital of Philadelphia and University of Pennsylvania

5:00 Immuno-Modulatory Activity of HDAC Inhibitors
Tso-Pang Yao, Ph.D., Associate Professor, Department of Pharmacology and Cancer Biology, Duke University

5:30 A Novel Zinc Binding Group Enables Selective Class Ila HDAC Inhibition and Alters Immune Responses
Mercedes Lobera, Ph.D., Head, Chemistry, Tempero Pharmaceuticals, Inc.

6:00 Close of Conference
TUESDAY, SEPTEMBER 24

7:00 am Registration and Morning Coffee

FEATURED SESSION: LEADERS IN EPIGENETIC DRUG DISCOVERY

8:10 Chairperson’s Opening Remarks

8:15 Drugging the Epigenome
Cheryl H. Arrowsmith, Ph.D., Chief Scientist, Structural Genomics Consortium; Professor, Medical Biophysics; Canada Research Chair, StructuralProteomics, University of Toronto

9:00 Drugging the Epigenome in Cancer
Peter J. Tummino, Ph.D., Head, Biology, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals

9:45 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

STATE OF THE ART IN LYSINE METHYLTRANSFERASE PROBES & INHIBITORS

10:45 A First-in-Class Chemical Probe for SETD7
Dafydd Owen, Ph.D., Associate Research Fellow, Medicinal Chemistry, Pfizer Worldwide R&D

11:15 Epigenetic Target Specificity and the Discovery of Epigenetic-Related in vivo Adverse Drug Reactions
Manilduth Ramnath, Ph.D., Project Manager, Custom Services and Innovation, Cerep

11:45 Targeting Histone Methyltransferases in Cancer Therapy
Sarah Knutson, Ph.D., Senior Scientist, Biological Sciences, Epizyme

12:15 pm Therapeutic Applications of EZH2 Small Molecule Inhibitors
Patrick Trojer, Ph.D., Senior Director & Head, Biology, Constellation Pharmaceuticals

12:45 Elimination of Serial Dilution to Improve Dose-Response Analyses
Ken Ward, Ph.D., Pharma Product Development R&D, Hewlett-Packard Company

NOVEL PROBES AND INHIBITORS: MECHANISTIC INSIGHTS INTO TARGET VALIDATION

2:15 Chairperson’s Opening Remarks

2:20 Targeting H3K4 Methylation by the MLL1 Complex for the Treatment of Mixed Lineage Leukemia
Yali Dou, Ph.D., Associate Professor, Pathology, University of Michigan

2:50 Small Molecule Epigenetic Intervention of Disease via Histone Lysine Methyltransferases
Matthew Fuchter, Ph.D., Senior Lecturer, Synthetic and Medicinal Chemistry, Department of Chemistry, Imperial College London

3:20 Sponsored Presentation (Opportunity Available)

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Harnessing EZH2 Enzymatic Activities by Targeting PRC2 Associated Cofactors
Gang “Greg” Wang, Ph.D., Assistant Professor, Department of Biochemistry & Biophysics, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

5:00 Targeting the Histone Methyltransferase MMSET in Cancer
Irfan Asangani, Ph.D., Research Investigator, Pathology, Michigan Center for Translational Pathology, University of Michigan

5:30 Interactive Breakout Discussion Groups

6:30 Welcome Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

WEDNESDAY, SEPTEMBER 25

7:30 am Registration and Morning Coffee

APPROACHES FOR HMT INHIBITOR DEVELOPMENT

8:00 Chairperson’s Opening Remarks

8:05 Global Analysis of Methylation and Functional Annotation of Methyltransferases: Chemo-Enzymatic Approaches
Zhaohui Sunny Zhou, Ph.D., Faculty Fellow, Barnett Institute of Chemical and Biological Analysis; Associate Professor, Department of Chemistry and Chemical Biology, Northeastern University

8:35 Hit-to-Lead Strategies for Epigenetic Targets at GSK
Alan P. Graves, Ph.D., Investigator, Platform Technology and Sciences, GlaxoSmithKline

9:05 Chemical Tractability of Protein Methyltransferases: Lessons Learned from Protein Structures and Screening Campaigns
Matthieu Schapira, Ph.D., Principal Investigator, Computational Chemistry, Structural Genomics Consortium; Associate Professor, Department of Pharmacology & Toxicology, University of Toronto

9:35 Sponsored Presentation (Opportunity Available)

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 Histone Methyltransferase Inhibitors Targeting Cancer
Yongcheng Song, Ph.D., Assistant Professor of Pharmacology, Baylor College of Medicine

11:20 The Structure and Activity of Type II Arginine Methyltransferases
Stephen Antonyamy, Ph.D., Principal Research Scientist, Structural Biology, Eli Lilly

11:50 Lunch On Your Own

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Close of Conference
Wednesday, September 25

11:50 am Registration
1:30 pm Chairperson’s Opening Remarks
1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details
3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

Towards Discovery of High-Quality Demethylase Probes

3:50 Chairperson’s Opening Remarks
4:00 Targeting H3K9me2 Writers and Erasers
Xiaodong Cheng, Ph.D., Professor of Biochemistry & Georgia Research Alliance Eminent Scholar, Emory University School of Medicine
4:30 Sponsored Presentations (Opportunities Available)
5:00 Structure and Specificity of JMJD2 Histone Demethylases
Raymond C. Trievel, Ph.D., Associate Professor of Biological Chemistry, University of Michigan Medical School
5:30 Strategies for Identifying New Chemical Probes for Histone Lysine Demethylases
Brian Lohse, Ph.D., Associate Professor, Drug Design and Pharmacology, University of Copenhagen
6:00 Nitric Oxide is an Endogenously Produced Epigenetic Regulatory Molecule
Douglas Thomas, Ph.D., Associate Professor, Medicinal Chemistry, University of Illinois at Chicago
6:30 Close of Day

Thursday, September 26

7:30 am Registration and Morning Coffee

Clinical Insights into Targeted Therapy
8:00 Breakfast Interactive Breakout Discussion Groups
9:05 Chairperson’s Opening Remarks
9:10 Chromatin Regulators as Therapeutic Targets in Breast Cancer
Kornelia Polyak, M.D., Ph.D., Associate Professor, Department of Medicine, Harvard Medical School; Associate Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute
9:40 Chromatin Modulators Provide a New Insight into Cancer Genomes

Johnathan R. Whetstone, Ph.D., Assistant Professor, Medicine, Harvard Medical School and Massachusetts General Hospital Cancer Center
10:10 Coffee Break in the Exhibit Hall with Poster Viewing
10:55 Epigenetic Therapy for Cancer Treatment
Lorraine Gudas, Ph.D., Chairman & Revlon Pharmaceutical Professor, Pharmacology and Toxicology, Pharmacology Department, Weill Cornell Medical College
11:25 Epigenetic Reprogramming in Pancreatic Cancer: The Emerging Role of Histone Demethylases
Alexandros Tzatsos, M.D., Ph.D., Instructor, Medicine, Harvard Medical School; Assistant Geneticist, Massachusetts General Hospital Cancer Center
11:55 Development of Histone Demethylase Inhibitors for Oncological and Neurodegenerative Disease
Tamara Maes, Ph.D., Co-Founder, Vice President & CSO, Oryzon Genomics
Oryzon's LSD1 inhibitors were shown to selectively abrogate the clonogenic potential of acute myeloid leukemia cells with MLL translocations, sparing the repopulating potential of normal hematopoietic stem cells. ORY-1001 is a potent, selective LSD1 inhibitor, with excellent pharmacological characteristics. ORY-1001 reduces leukemic stem cell potential, potently inhibits colony formation, overcomes the differentiation block in AML cell lines, and induces apoptosis/inhibits proliferation at sub-nanomolar concentrations in selected AML cell lines. ORY-1001 has received a positive opinion for orphan drug status for AML from the EMA and will start Phase I studies in Q4 2013.
12:25 pm Sponsored Presentation (Opportunity Available)
12:55 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

Perturbing the Histone Demethylome: Novel Modulators & Insights into Inhibition
2:25 Chairperson’s Opening Remarks
2:30 Targeting the Histone Demethylome
Udo Oppermann, Ph.D., Professor, Molecular Biology; Director, Molecular Laboratory Sciences, Bonnar Research Centre; Principal Investigator, Epigenetics and Metabolism, Structural Genomics Consortium, University of Oxford
3:00 Targeting Histone Demethylation in Cancer
Ryan Kruger, Ph.D., Manager, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals
3:30 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Targeting Lysine-Specific Demethylase 1 with Polyamine Analogues to Induce Expression of Aberrantly Silenced Genes
Robert A. Casero, Jr., Ph.D., Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
4:30 JIB-04 is a Novel Small Molecule Inhibitor of Jumonji Demethylases with Anti-Cancer Activity In Vivo
Elisabeth Martinez, Ph.D., Assistant Professor, Pharmacology, University of Texas Southwestern Medical Center
5:00 JARID1 Demethylases as Cancer Targets
Qin Yan, Ph.D., Assistant Professor, Pathology, Yale University School of Medicine
5:30 The Therapeutic Potential of Jumonji Histone Demethylase Inhibitors
Peter Staller, Ph.D., Director, Oncology Research, Epitheraapeutics ApS
6:00 Close of Conference
**SUGGESTED EVENT PACKAGE**
September 23: Setting Up Effective RNAi Screens: Getting From Design to Data **Short Course 6**
September 24-25: Functional Genomics Screening Strategies **Conference Part One**
September 25: Setting Up Effective Functional Screens Using 3D Cell Cultures **Dinner Short Course 9**
September 25-26: Functional Genomics Screening Strategies **Conference Part Two**

**TUESDAY, SEPTEMBER 24**

7:00 am Registration and Morning Coffee

WHERE AND HOW TO APPLY siRNA AND shRNA SCREENS

8:10 Chairperson’s Opening Remarks

8:15 Comparative Analysis of Arrayed RNAi Screening Performance of siRNA versus shRNA at Genome-Scale
Hakim Djabbalah, Ph.D., Director, HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center

8:45 Swimming in the Deep End – Sources Leading to a False Sense of Security in RNAi Screen Data
Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Institutes for Health

9:15 Rebuilding the RNAi Screen
Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health

9:45 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

10:45 RNAi Screening: Strategies, Examples and Outcomes
David Root, Ph.D., Director, RNAi Platform and Project Leader, The RNAi Consortium, The Broad Institute of MIT and Harvard

11:15 Rapid RNAi-based In Vivo Screening in Mice
Daniel Schramek, Ph.D., Emerald Foundation Young Investigator, Human Frontier of Science Postdoctoral Fellow, Howard Hughes Medical Institute HHMI, Laboratory of Mammalian Cell Biology and Development, Rockefeller University

11:45 PANEL DISCUSSION: Advanced RNAi Screening: Strengths, Caveats and Pitfalls at Reaching the 14-Year Milestone
Moderator: Chrstophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience USA, Inc. Panelists:
Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility, Harvard Medical School
David Root, Ph.D., Director, RNAi Platform and Project Leader, The Broad Institute Hakim Djabbalah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center
Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center

12:45 pm Luncheon Presentation: Screening with MISSION® miRNA inhibitors and Pooled shRNA Libraries
Shawn L. Shafer, Ph.D., Market Segment Manager, Functional Genomics, Sigma® Life Science

**FUNCTIONAL GENOMICS SCREENING STRATEGIES**
Part One: Utilizing RNA Interference (RNAi) Screens to Explore Drug Targets and Cellular Pathways

Cardiovascular Disease
Heiko Runz, M.D., Group Leader, Institute of Human Genetics, University of Heidelberg and Group Leader, Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/EMBL

3:20 Pooled RNAi Genetic Screening to Identify Functional Genes and Novel Drug Targets
Paul Diehl, Ph.D., Director, Business Development, Cellecta, Inc.

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Cell-Based Small Molecule and siRNA Screen to Identify Targets for Retinal Neuroprotection
Donald J. Zack, M.D., Ph.D., Professor, Departments of Ophthalmology, Molecular Biology and Genetics, and Neuroscience, Johns Hopkins University School of Medicine

5:00 Deep Coverage shRNA Screens for Epigenetics Target Discovery
Gregory Hoffman, Ph.D., Investigator II, Novartis Institutes for Biomedical Research

5:30 Interactive Breakout Discussion Groups

6:30 Welcome Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

**WEDNESDAY, SEPTEMBER 25**

7:30 am Registration and Morning Coffee

COMBINING USE OF RNAi AND OTHER TECHNOLOGIES

8:00 Chairperson’s Opening Remarks

8:05 RNAi Screening to Enable Translational R&D For Oncology and Immuno-Oncology Target Discovery
Namjin Chung, Ph.D., Senior Research Investigator, Applied Genomics, Bristol Myers Squibb Co.

8:35 siRNA Screening and RNA-seq for Identification of Targets for the Treatment of Alzheimer’s Disease
Paul Kassner, Ph.D., Director, Research, Amgen, Inc.

9:05 Fusing RNAi Screening and Gene Expression Analyses to Reveal Pathway Responses
Alexander Bishop, Ph.D., Assistant Professor, Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio

9:35 From High-Throughput Screens to Biomedical Knowledge
Frank Buchholz, Ph.D, Professor, Medical Systems Biology, University Hospital and Medical Faculty Carl Gustav Carus, Technical University Dresden

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 Use of Functional Genomics to Identify Patients at High Risk for Recurrence of Hepatitis C Following Liver Transplantation
Robert Canthers, M.D., Professor of Medicine, Director, Liver Care Line and Medical Director of the Liver Transplant Program, University of Washington Medical Center

11:20 TECHNOLOGY PANEL: Tools for Next-Generation Functional Genomics Screens
Moderator: Chrstophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience USA, Inc. Panelists:
Paul Diehl, Ph.D., Director, Business Development, Cellecta, Inc.
Pram K. Premrurut, Ph.D., President & CEO, Minnus, Inc.
Louise Baskin, Senior Product Manager, Marketing, ThermoFisher Scientific
Shawn L. Shafer, Ph.D., Market Segment Manager, Functional Genomics, Sigma® Life Science

11:50 Lunch on Your Own

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Close of Conference
Functional Genomics Screening Strategies
Part Two: Exploring Novel Screening Platforms and Cellular Models for Next-Generation Screens

SUGGESTED EVENT PACKAGE
September 23: Setting Up Effective RNAi Screens: Getting From Design to Data Short Course 6
September 24-25: Functional Genomics Screening Strategies Conference Part One
September 25: Setting Up Effective Functional Screens Using 3D Cell Cultures Dinner Short Course 9
September 25-26: Functional Genomics Screening Strategies Conference Part Two

WEDNESDAY, SEPTEMBER 25

11:50 am Registration

SYNERGISTIC USE OF RNAi AND CHEMICAL GENOMICS SCREENS

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Chairperson’s Opening Remarks

4:00 The Role and Positioning of RNAi in Our Approach to Target and Biomarker Discovery
John N. Feder, Ph.D., Associate Director, Genome Biology, Applied Genomics, Bristol-Myers Squibb Co.

4:30 Sponsored Presentations (Opportunities Available)

5:00 Utilization of siRNA and Small Molecule Screens to Elucidate Cellular Pathways Involved in HPV-Associated Cancers
Jennifer Smith, Ph.D., Assistant Director, ICCB-Longwood Screening Facility, Harvard Medical School

5:30 Compound Synergy via Genomics and Combinatorics
Matthew Tudor, Ph.D., Principal Scientist, Screening & Protein Sciences, Merck Research Laboratories

6:00 Size Exclusion Chromatography Target Identification (SEC-TID): A Label-Free Method for Small Molecule Target Identification
Gregory Michaud, Ph.D., Senior Investigator I, Developmental & Molecular Pathways, Novartis Institutes for BioMedical Research

6:30 Close of Day

THURSDAY, SEPTEMBER 26

7:30 am Registration

USE OF 3D CELL CULTURES FOR FUNCTIONAL SCREENING

8:00 Breakfast Interactive Breakout Discussion Groups

9:05 Chairperson’s Opening Remarks

9:10 Disease & Risk On Chips: 3D Culture to Improve Development and Assessment of Drugs for Prevention and Treatment of Breast Cancers
Sophie Leclère, D.V.M., L.L.M., Ph.D., Associate Professor, Department of Basic Medical Sciences; Associate Director, Discovery Groups, NCI-Designated Purdue Center for Cancer Research, Purdue University

9:40 Targeting Cancer Stem Cells: A Model Demonstrating the Advantages and Disadvantages of 3D qHTS Technology in vitro
Lesley Mathews, Ph.D., Research Scientist, Biomolecular Screening and Profiling/Probe Development Group, National Center for Advancing Translational Sciences, NIH

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:55 Multi-Cellular 3D Tumor Spheroid Models for High-Throughput Screening in Cancer Biology
Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

11:25 Image Analysis Workflows for High Throughput 2D/3D Screens
Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center

11:55 PANEL DISCUSSION: Pros and Cons of Working with 3D Cell Cultures
Moderator: Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, The University of Texas MD Anderson Cancer Center
Panelists: Session Speakers

12:25 pm Sponsored Presentation (Opportunity Available)

12:55 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

IN VIVO RNAi SCREENING

2:25 Chairperson’s Opening Remarks

2:30 Pooled RNAi Screens in Xenograft Mouse Models
Sponsored by
Donato Tedesco, Ph.D., Lead Research Scientist, Cellecta, Inc.

3:00 RNAi Mouse Models: revolutionizing Drug Discovery in vivo
Sponsored by
Prem K. Premsrirut, Ph.D., President & CEO, Mirimus, Inc.

3:30 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing

STEM CELL AND LONG NON-CODING RNA (IncRNA)-BASED SCREENS

4:00 Functional Genomics, a Novel Stem Cell-Based Screening Platform
Scott Noggle, Ph.D., Director and Charles Evans Senior Research Fellow for Alzheimer’s Disease, The New York Stem Cell Foundation

4:30 Primary Neural Stem Cell-based High Throughput High Content Phenotypic Screening for Multiple Sclerosis
Mei Zhang, M.D., Ph.D., Senior Scientist, Molecular Pharmacology, Small Molecule Platforms, EMD Serono Research and Development Institute, Inc.

5:00 Long Non-Coding RNAs as Targets for High-Throughput Functional Screens
Marcel Dinger, Ph.D., Head, Genome Informatics, The Kinghorn Cancer Centre, Garvan Institute for Medical Research; Associate Professor, Faculty of Medicine, University of New South Wales, Sydney, Australia

5:30 Presentation to be Announced

6:00 Close of Conference
**SUGGESTED EVENT PACKAGE**

September 23: Practical Aspects of Structure-Based Drug Discovery with GPCRs **Short Course 2**

September 23: Allosteric Modulators of GPCRs **Short Course 4**

September 24-25: GPCR-Based Drug Discovery Conference

September 25-26: GPCR-Targeted Therapies Conference

---

**TUESDAY, SEPTEMBER 24**

7:00 am Registration and Morning Coffee

**G PROTEIN-COUPLED RECEPTOR STRUCTURE**

8:10 Chairperson’s Opening Remarks
Andrew Alt, Ph.D., Senior Research Investigator II, Lead Discovery, Bristol Myers Squibb and Co.

8:15 Structural insights into Function and Pharmacology of GPCR Superfamily
Vsevolod (Seval) Katritch, Ph.D., Assistant Professor, The Scripps Research Institute

8:45 FEATURED PRESENTATION: Molecular Signatures of GPCRs
Christopher Tate, Ph.D., Professor, Laboratory of Molecular Biology, MRC, United Kingdom

9:15 GPCR Ligand Design via SAR-Guided Homology Models
Mark Bures, Ph.D., Research Advisor, Computational Chemistry, Eli Lilly

9:45 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

**ANTIBODIES AND GPCRs**

10:45 Nanobodies for the Structural and Functional Characterization of GPCR Transmembrane Signaling: From Structure to Function to Drugs
Jan Steyaert, Ph.D., Head of Department, Structural Biology, Vrije University Brussels, Belgium

11:15 Antibodies Against Difficult Targets: How to Tackle G-Protein Coupled Receptors
Stefanie Urringer, Ph.D., Director, Research & Development, MorphoSys AG

11:45 Monoclonal Antibodies against Endothelin A and B Human GPCR Subtypes
Frederic Ducancel, Ph.D., Head, Laboratory, Institute of Biology and Technology, Saclay, Atomic Energy Commission, France

12:15 A Novel Regulatory Role of a Humanized Anti-CCR4 Antibody in Cancer Immunotherapy
Dekuan Chang, Ph.D., Research Fellow, Cancer Immunology & AIDS, Dana-Farber Cancer Institute

12:45 LUNCHEON PRESENTATION: New Era of GPCR Drug Discovery: Multi-Pathway Screening Technologies
Elizabeth R. Quinn, Ph.D., Director, LeadHunter Discovery Services, DiscoveRx Corporation

**LIGAND-BASED SIGNALING**

2:15 Chairperson’s Opening Remarks
Dave Unett, Ph.D., Vice President, Receptor Pharmacology, Arena Pharmaceuticals

2:20 FEATURED PRESENTATION: Allosteric Regulation of G Protein-Coupled Receptors: Implications to Functionally Selective Ligand Pharmacology
Roger K Sunahara, Ph.D., Associate Professor, Pharmacology, University of Michigan Medical School

---

**WEDNESDAY, SEPTEMBER 25**

7:30 am Registration and Morning Coffee

**NEW APPROACHES FOR ALLOSTERICS, INTERNALIZATION AND OTHER PHARMACOLOGIC CHALLENGES**

8:00 Chairperson’s Opening Remarks
Dario Doller, Ph.D., Director, Discovery Chemistry & DMPK, Lundbeck Research USA

8:05 Functional Evaluation of 5-HT2C Receptor Agonists for Obesity
Dave Unett, Ph.D., Vice President, Receptor Pharmacology, Arena Pharmaceuticals

8:35 Label-free Assays to Probe Ligand-Biased Signaling
Hong Xin, Ph.D., Principal Scientist, CREATe Core technologies, Janssen R&D

9:05 Structure of FSH and Receptor Ectodomain Complex: Relevance to the Discovery of Small Molecule Allosteric Modulators
Xuliang Jiang, Ph.D., Associate Director, Structural Biology and Computational Chemistry, EMD Serono

9:35 Report-Back from Breakout Discussion Moderators

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 The “No Ligand Depletion” Assumption Is Unnecessary and Can Be Misleading
Gilles Ginacadia, Ph.D., Principal Analyst, System Informatics, Amgen

11:20 Discovery of Positive Allosteric Modulators of the Mu-Opioid Receptor
Neil Burford, Ph.D., Senior Research Investigator II, Lead Discovery & Profiling, Molecular Sciences and Candidate Optimization, Bristol-Myers Squibb Company

11:50 Lunch on Your Own

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Close of Conference
WEDNESDAY, SEPTEMBER 25

11:50 am Registration

ALLOSTERIC MODULATORS IN DEVELOPMENT

1:30 pm Chairperson’s Opening Remarks

1:40 PLENARY KEYNOTE PRESENTATIONS

See Page 3 for Details

3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Chairperson’s Opening Remarks

Corey Hopkins, Ph.D., Research Assistant Professor, Pharmacology, Vanderbilt University

4:00 FEATURED SPEAKER: Something Old, Something New, Something Borrowed, Something Glu: Lessons Learned in the Design of Ligands for Metabotropic Glutamate Receptors

Dario Doller, Ph.D., Director, Discovery Chemistry & DMPK, Lundbeck Research USA

4:30 Advancing GPCR-Targeted Allosteric Modulators as Novel Therapeutics for Severe CNS Disorders

Sylvain Celanire, Ph.D., former Associate Research Director, Medicinal Chemistry, Addex; Independent Pharmaceutical Professional

5:00 Novel mGlu4 Positive Allosteric Modulators for the Treatment of Parkinson’s Disease

Corey Hopkins, Ph.D., Research Assistant Professor, Pharmacology, Vanderbilt University

5:30 Technology Combination to Address GPCR Allosteric Modulator Drug Discovery Pitfalls

Stephan Schann, Ph.D., Head, Research, Domain Therapeutics, SA

6:00 Q&A with Session Speakers

6:30 Close of Day

THURSDAY, SEPTEMBER 26

7:30 am Registration

GPCR TARGETS IN THE CNS

8:00 Breakfast Interactive Breakout Discussion Groups

9:05 Chairperson’s Opening Remarks

Fiona Scott, Ph.D., Associate Director, Biology, Receptos

9:10 Prioritizing Dementia Indications for a Novel Cognition Drug: A Case Study for Selective Muscarinic Agonists

Dan Grau, Ph.D., President, Heptares

9:40 High-throughput Discovery of Small Molecules Targeting Orphan GPCRs

Alexander Gragerov, Ph.D., Senior Director of Research, Omeros Corporation

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

THERAPEUTIC ANTIBODIES AGAINST GPCRs

10:55 An Allosteric Therapeutic Antibody Targeting the Glucagon Receptor

Bernard Allan, Ph.D., Senior Scientist, Department of Molecular Biology, Genentech

Novel Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor

Peter Ravn, Ph.D., Senior Research Scientist, Department of Antibody Discovery and Protein Engineering, MedImmune Ltd.

11:25 Novel Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor

Peter Ravn, Ph.D., Senior Research Scientist, Department of Antibody Discovery and Protein Engineering, MedImmune Ltd.

11:55 Report-back from Breakout Discussion Moderators

12:25 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

MULTI-FUNCTIONAL GPCR TARGETS

1:55 Chairperson’s Opening Remarks

Changlu Liu, Ph.D., Scientific Director, Janssen Fellow, Head of Molecular Innovation, Neuroscience, Janssen Research & Development, LLC

2:00 Discovery and Preclinical Development of RPC1063, an S1P1R Modulator, for the Treatment of Patients with Relapsing Multiple Sclerosis and Ulcerative Colitis

Fiona Scott, Ph.D., Associate Director, Biology, Receptos

2:30 EBI2 – A Moving Target – A Recently De-Orphanized GPCR

Mette Rosenkilde, Ph.D., Professor, Neuroscience and Pharmacology, University of Copenhagen

3:00 Targeting the Ghrelin Receptor with an Oral, Macro cyclic Agonist

Mark L. Peterson, Ph.D., Vice President, IP and Operations, Tranzyme Pharma

3:30 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing

GPCR’S IN METABOLIC DISEASES

4:00 Lactate Receptor, GPR81/HCA1, as a Novel Target for Metabolic Disorders

Changlu Liu, Ph.D., Scientific Director, Janssen Fellow, Head of Molecular Innovation, Neuroscience, Janssen Research & Development, LLC

4:30 Targeting GPR55 in Cancer and Diabetes

Marco Falasca, Ph.D., Professor of Molecular Pharmacology, Queen Mary University of London

5:00 TGR5 in Metabolic Diseases

Michael Orsini, Ph.D., Principal Scientist, Diabetes Drug Discovery, Bristol-Myers Squibb

5:30 Close of Conference
Seventh Annual ■ September 24 - 25, 2013
Novel Strategies for Kinase Inhibitors
Exploring New Therapeutic Areas

SUGGESTED EVENT PACKAGE
September 23: New Class of Kinase Inhibitors: Covalent Modifiers
Short Course 1
September 23: Advancing Tools and Technologies for Fragment-Based Design Short Course 5
September 24-25: Novel Strategies for Kinase Inhibitors Conference
September 25-26: Cardio-Metabolic Drug Targets Conference

TUESDAY, SEPTEMBER 24
7:00 am Registration and Morning Coffee

BEYOND CANCER

8:10 Chairperson’s Opening Remarks
John Robinson, Ph.D., Senior Scientist, Medicinal Chemistry, Array BioPharma Inc.

8:15 Second Generation Janus Kinase Inhibitors
Jordan S. Fridman, Ph.D., Senior Director, Pharmacology, Incyte Corp.

8:45 BTK Inhibitors in Inflammation and Autoimmunity
John Douhan III, Ph.D., Senior Principal Scientist, Immunoscience, Pfizer

9:15 ARRY-382, a Selective cFMS Inhibitor for the Treatment of Osteolytic Bone Diseases
John Robinson, Ph.D., Senior Scientist, Medicinal Chemistry, Array BioPharma Inc.

9:45 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Targeting B-Cell Receptor Signaling with PI3Kdelta Inhibitors for Treatment of Inflammatory Diseases and B-cell Malignancies
Kamal Puri, Ph.D., Associate Director, Research, Gilead Sciences, Inc.

11:15 A Recombinant ATM Enzyme for Drug Discovery and Screening Applications
Phil Adams, Ph.D., Manager, Research Development, Discovery & Development Solutions, Merck

11:45 Deregulated Cdk5-Targeted Inhibitor for Neuro-inflammation
Harish C. Pant, Ph.D., Chief, Laboratory of Cytoskeleton Protein Regulation, National Institute of Neurological Disease and Stroke/NIMH

12:15 pm Orally Available, CNS Penetrant MLK Inhibitors for Treatment of Neurodegenerative Diseases
Val Goodfellow, Ph.D., CEO, Califia Bio, Inc.

12:45 Lunch on Your Own

ALLOSTERIC KINASE INHIBITORS

2:15 Chairperson’s Opening Remarks
William J. Pitts, Ph.D., Group Leader, Medicinal Chemistry, Bristol Myers Squibb Co.

2:20 JNK Inhibitor Discovery at Celgene – Tansizertib and Beyond
Yoshitaka Satoh, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Celgene

2:50 Highly Selective Allosteric FMS Kinase Inhibitors
Bryan Smith, Ph.D., Director, Biology, Deciphera Pharmaceuticals LLC

3:20 The Design and Optimization of selective PKCθ Inhibitors for the Treatment of MS
Philip Collier Ph.D., Senior Research Scientist, Medicinal Chemistry, Vertex Pharmaceuticals

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 P529, An Allosteric Modifier of the TORC1 and TORC2 Complexes of the PI3K/Akt/mTOR Pathway
David Sherris, Ph.D., President and CEO, Paloma Pharmaceuticals, Inc.

5:00 Allosterically Targeting Polo-Like Kinase 1 for Selective Cancer Cell Killing
Kyung Lee, Ph.D., Senior Investigator, Section Head, Laboratory of Metabolism, National Cancer Institute

5:30 Interactive Breakout Discussion Groups

6:30 Welcome Reception in the Exhibit Hall with Poster Viewing

7:30 pm Close of Day

WEDNESDAY, SEPTEMBER 25

7:30 am Registration and Morning Coffee

OVERCOMING CANCER DRUG RESISTANCE AND SELECTIVE KINASE INHIBITORS

8:00 Chairperson’s Opening Remarks
Jordan S. Fridman, Ph.D., Senior Director, Pharmacology, Incyte Corp.

8:05 FEATURED SPEAKER: The Role of Growth Factors in Resistance to Anti-Cancer Kinase Inhibitors
Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech

8:35 FEATURED SPEAKER: Stromal Factors that are Targets for PI-3 Kinase Inhibitor Therapeutics in the Control of Metastasis
Donald L. Durden, M.D., Ph.D., Professor, Department of Pediatrics; Director Pediatric Oncology Research, University of California, San Diego and CEO, SignalRx Pharmaceuticals

9:05 mTOR Inhibitor Torin-1 for Effective Targeting of Resistant Human Colon Cancer Stem Cells
Maria Giovanna Francipane, Ph.D., Post Doctoral Research Scholar, Pathology, University of Pittsburgh

9:35 Panel Discussion: Kinase Inhibitor Discovery Challenges

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 Development of c-MeT Kinase Inhibitors for Cancer Therapy and Drug Resistance
Xiangdong Liu, Ph.D., Drug Discovery Group, Incyte Corporation

11:20 Exploiting a Serendipitous Binding Opportunity in the Development of Highly Selective Rho Kinase Inhibitors
Erick Young, Ph.D., Distinguished Research Fellow, Medicinal Chemistry and Research Administration, Boehringer Ingelheim Pharma

11:50 Lunch On Your Own

1:40 PLenary KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Close of Conference
Inaugural September 25 - 26, 2013
Cardio-Metabolic Drug Targets
Targeting One, Treating More

**SUGGESTED EVENT PACKAGE**
- September 23: Allosteric Modulators of GPCRs **Short Course 4**
- September 24-25: Novel Strategies for Kinase Inhibitors **Conference**
- September 25: Setting Up Effective Functional Screens Using 3D Cell Cultures **Dinner Short Course 9**
- September 25-26: Cardio-Metabolic Drug Targets **Conference**

**WEDNESDAY, SEPTEMBER 25**

11:50 am Registration

**BEYOND STATINS: NEW APPROACHES FOR REGULATING LIPID METABOLISM AND ATHEROSCLEROSIS**
1:30 pm Chairperson’s Opening Remarks
1:40 **PLENARY KEYNOTE PRESENTATIONS**
See Page 3 for Details

3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Chairperson’s Opening Remarks
Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals

4:00 **FEATURED SPEAKER:** Atherosclerosis and Cardio-Metabolism Research Overview: Promising Targets
Margit Schwarz, Ph.D., MBA, MS Consulting, LLC; formerly Director of Research, Dyslipidemia and Atherosclerosis, Amgen

**Sponsored by**

4:30 Combining Next-Generation Phenotyping with Panomics – A New Standard for Biomarker and Drug Discovery
Szilard Voros, M.D., Founder & CEO, Global Genomics Group LLC

5:00 Novel Treatment for Dyslipidemia: Liver-Directed Thyroid Hormone-ß Agonist
Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals

5:30 Modulating Glycerolipid Metabolism in Myeloid Cells for Cardiometabolic Benefit
Suneil K. Koliwad, MD., Ph.D. Assistant Professor, Diabetes Center/Department of Medicine, University of California San Francisco (UCSF)

6:00 Targeting PCSK9 for Hypercholesterolemia and Atherosclerosis
Hong Liang, Ph.D., Associate Research Fellow, Rinat Research Unit, Pfizer

6:30 Close of Day

**THURSDAY, SEPTEMBER 26**

7:30 am Registration

**NEW ARTHERO/LIPID/CARDIO-METABOLIC DRUG TARGETS**

8:00 Breakfast Interactive Breakout Discussion Groups

9:05 Chairperson’s Opening Remarks

9:10 ApoE derived ABCA1 agonists for the Treatment of Cardiovascular Disease
Jan Johansson, M.D., Ph.D., CEO, Artery Therapeutics, Inc.

9:40 Blockade of Delta-Like Ligand 4 (DII4)-Notch Signaling

**CARDIO-METABOLIC MIMETICS**
1:55 Chairperson’s Opening Remarks
Ajit Srivastava, Ph.D., Independent Consultant, Integrated Pharma Solutions, LLC

2:00 Oral Mimetics of RYGB and GLP-1 in Metabolic Syndromes
Jerome J. Schentag, PharmD, Professor of Pharmaceutical Sciences, University at Buffalo

2:30 Expert Panel Discussion: Challenges in Diabetes and Atherosclerosis Drug Development
Moderator: Jerome J. Schentag, PharmD, Professor of Pharmaceutical Sciences, University at Buffalo
Panelists:
- Paul L. Feldman, Ph.D., Senior Vice President, GlaxoSmithKline
- Jan Johansson, M.D., Ph.D., CEO, Artery Therapeutics, Inc.
- Ajit Srivastava, Ph.D., Independent Consultant, Integrated Pharma Solutions, LLC
- Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals

3:00 TGR5 in Metabolic Diseases
Michael Orsini, Ph.D., Principal Scientist, Diabetes Drug Discovery, Bristol-Myers Squibb

3:30 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing

**GPCRS IN METABOLIC DISEASES**
4:00 Lactate Receptor, GPR81/HCA1, as a Novel Target for Metabolic Disorders
Changliu Liu, Ph.D., Scientific Director, Janssen Fellow, Head of Molecular Innovation, Neuroscience, Janssen Research & Development, LLC

4:30 Targeting GPR55 in Cancer and Diabetes
Marco Falaschi, Ph.D., Professor of Molecular Pharmacology, Queen Mary University of London

5:00 Close of Conference
TUESDAY, SEPTEMBER 24

7:00 am Registration and Morning Coffee

BIOLoGY OF GPCR ANTIBODy TARGETS

8:10 Chairperson’s Opening Remarks
Christopher Koth, Ph.D., Senior Scientist, Structural Biology, Genentech

8:15 FEATURED PRESENTATION: Probing GPCR Dynamics Using Genetically-Encoded Unnatural Amino Acids
Thomas P. Sakmar, M.D., Richard M. & Isabel P. Furlaud Professor, Laboratory of Chemical Biology & Signal Transduction, The Rockefeller University

9:15 LY2951742, an Antibody to Calcitonin Gene-Related Peptide (CGRP) for Prevention of Migraine Headaches
David S. Grayzel, M.D., CEO, Arteaus Therapeutics

10:45 Nanobodies for the Structural and Functional Characterization of GPCR Transmembrane Signaling: From Structure to Function to Drugs
Jan Steyaert, Ph.D., Head of Department, Structural Biology, Vrije University Brussels, Belgium

11:15 Antibodies Against Difficult Targets: How to Tackle G-Protein Coupled Receptors
Stefanie Urlander, Ph.D., Director, Research & Development, MorphoSys AG

11:45 Monoclonal Antibodies Against Endothelin A and B Human GPCR Subtypes
Frederic Ducancel, Ph.D., Head of Laboratory, Institute of Biology and Technology, Saclay, Atomic Energy Commission, France

12:15 A Novel Regulatory Role of a Humanized Anti-CR4 Antibody in Cancer Immunotherapy
DeKuan Chang, Ph.D., Research Fellow, Cancer Immunology & AIDS, Dana-Farber Cancer Institute

12:45 LUNCHEON PRESENTATION: New Era of GPCR Drug Discovery: Multi-Pathway Screening Technologies
Elizabeth R. Quinn, Ph.D., Director, LeadHunter Discovery Services, DiscoverRx Corporation

WEDNESDAY, SEPTEMBER 25

7:30 am Registration and Morning Coffee

ION CHANNELS AND OTHER TARGETS

8:05 Chairperson’s Opening Remarks
Matthew Gardner, Ph.D., Senior Scientist, ADPE, MedImmune, United Kingdom

8:05 FEATURED PRESENTATION: Protease-Resistant IgG Platform Targeting Cell Surface Proteins for Anti-Tumor and Anti-Bacterial Therapy
William R. Stohl, Ph.D., Vice President, Biologics Research, Janssen Research & Development, LLC

8:35 Antibody Therapeutics Targeting Ion Channels: Are We There Yet?
Han Sun, Researcher, The Solomon H. Snyder Department of Neuroscience, Johns Hopkins Ion Channel Center, High Throughput Biology Center, School of Medicine, Johns Hopkins University

9:05 Ion Channels as Targets for Monoclonal Antibodies
Matthew Gardner, Ph.D., Senior Scientist, ADPE, MedImmune, United Kingdom

9:35 Novel Strategies for Identification and Characterization of Human Antibodies Against Nav1.7 Ion Channel Target
Hans de Haard, Ph.D., Professor, University of Utrecht, CSO, aRGEN-X BV

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 XMETs, an Allosteric Modulator Antibody to the Insulin Receptor (INSR) that Enhances Insulin Binding to INSR and Restores Glycemic Control in Mouse Models of Diabetes
Hassan Issafras, Ph.D., Senior Scientist, Molecular Interactions & Biophysics, P2X7 ion Channel

11:20 Engineering Novel Therapeutics Targeting the Ion Channel Kv1.3
Ronald V. Swanson, Ph.D., President and CSO, Integral Molecular, Inc.

11:50 Lunch on Your Own

1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details

3:10-3:50 pm Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Close of Conference
WEDNESDAY, SEPTEMBER 25

11:50 am Registration
1:30 pm Chairperson’s Opening Remarks
1:40 PLENARY KEYNOTE PRESENTATIONS
See Page 3 for Details
3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

STRUCTURAL BIOLOGY AND CHARACTERIZATION OF ANTIBODY-MEMBRANE PROTEIN INTERACTIONS

3:50 Chairperson’s Remarks
Hassan Issafras, Ph.D., Senior Scientist, Molecular Interactions & Biophysics, Preclinical Research, XOMA Corp.
4:00 Synthetic Antibodies to Probe the Structural and Conformational Diversity of GPCRs and Their Signaling Complexes
Arun Shukla, Ph.D., Assistant Professor, Medicine, Duke University Medical Center
4:30 Suggested Presentations (Opportunities Available)
5:00 Antibody Inhibition of Bacterial Manganese Transport
Christopher Koth, Ph.D., Senior Scientist, Structural Biology, Genentech
5:30 On-Cell, Solution Binding Affinity Measurements for Membrane Targets
Palaniswami Rathanaswami, Ph.D., Senior Scientist, Amgen, Canada
6:00 Therapeutic Targeting of Homeostatic Chemokine Receptors with Antibodies
Eldar Kim, Ph.D., Chief Scientific Officer, MSM Protein Technologies, Inc.
6:30 Close of Day

THURSDAY, SEPTEMBER 26

7:30 am Registration

MEMBRANE PROTEIN EXPRESSION AND IMMUNIZATION TECHNOLOGIES

8:00 Breakfast Interactive Breakout Discussion Groups
9:05 Chairperson’s Opening Remarks
Partha Chowdhury, Ph.D., Principal Scientist, MedImmune
9:10 Evolution of Stable and High Expressing GPCRs for Structure Determination and as Screening Targets
Pascal Egloff, Ph.D., Scientist, Plückthun Laboratories, Biochemistry Institute, University of Zürich, Switzerland
9:40 Application of Tetrahymena Thermophila as an Alternative Platform for Difficult to Express Immunogens
Gregory Carven, Ph.D., Associate Research Fellow, Head of Hybridoma Research, Pfizer
### Pricing and Registration Information

#### SHORT COURSES

<table>
<thead>
<tr>
<th></th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>One short course</td>
<td>$695</td>
<td>$395</td>
</tr>
<tr>
<td>Two short courses</td>
<td>$995</td>
<td>$595</td>
</tr>
<tr>
<td>Three short courses</td>
<td>$1195</td>
<td>$695</td>
</tr>
<tr>
<td>Registered Conference Delegates SAVE $100</td>
<td>-$100</td>
<td>-$100</td>
</tr>
</tbody>
</table>

Monday, September 23

- SC1: New Class of Kinase Inhibitors: Covalent Modifiers
- SC2: Practical Aspects of Structure-Based Drug Discovery with GPCRs
- SC3: Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery
- SC4: Allosteric Modulators of GPCRs
- SC5: Advancing Tools and Technologies for Fragment-Based Design
- SC6: Setting Up Effective RNAi Screens: Getting From Design to Data
- SC7: Production and Presentation of Integral Membrane Proteins for Antibody Discovery
- SC8: Characterization and Quantification of Histone Modifications

Wednesday, September 25

- SC9: Setting Up Effective Functional Screens Using 3D Cell Cultures
- SC10: Tools for Epigenetic Biomarker Discovery

### CONFERENCE PRICING

#### STANDARD PACKAGE
(Includes access to 2 conferences. Excludes short courses.)

| Registrations after August 23, 2013, and on-site | $2575 | $1195 |

#### SINGLE CONFERENCE PACKAGE
(Includes access to 1 conference. Excludes short courses.)

| Registrations after August 23, 2013, and on-site | $1745 | $975  |

<table>
<thead>
<tr>
<th>September 24 - 25</th>
<th>September 25 - 26</th>
</tr>
</thead>
<tbody>
<tr>
<td>Track 1: Targeting Epigenetic Readers</td>
<td>Track 7: Next-Generation Histone Deacetylase Inhibitors</td>
</tr>
<tr>
<td>Track 2: Targeting Histone Methyltransferases</td>
<td>Track 8: Targeting Histone Demethylases</td>
</tr>
<tr>
<td>Track 3: GPCR-Based Drug Discovery</td>
<td>Track 9: GPCR-Targeted Therapeutics</td>
</tr>
<tr>
<td>Track 5: Novel Strategies for Kinase Inhibitors</td>
<td>Track 11: Cardio-Metabolic Drug Targets</td>
</tr>
<tr>
<td>Track 6: Antibodies Against Membrane Protein Targets - Part 1</td>
<td>Track 12: Antibodies Against Membrane Protein Targets - Part 2</td>
</tr>
</tbody>
</table>

### Student Fellowship

Discovery on Target is pleased to announce its Inaugural Annual Student Fellowship! Full time graduate students and Ph.D. Candidates are encouraged to apply for the Discovery on Target Student Fellowship; applications are due by July 19, 2013. This fellowship is limited to 10 students. For more information, visit: DiscoveryOnTarget.com.

If you are unable to attend but would like to purchase the Discovery On Target CD for $750 (plus shipping), please visit DiscoveryOnTarget.com. Massachusetts delivery will include sales tax.

### CONFERENCE DISCOUNTS

#### POSTER DISCOUNT ($50 OFF)
Poster abstracts are due by August 16, 2013. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

#### REGISTER 3 - 4th IS FREE:
Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

#### ALUMNI DISCOUNT:
Cambridge Healthtech Institute (CHI) appreciates your past participation at Discovery On Target. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

Alumni and Register 3-4th is free discounts cannot be combined

#### GROUP DISCOUNTS:
Discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

### ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

To view our Substitutions/ Cancellations Policy, go to http://www.healthtech.com/regdetails

Video and or audio recording of any kind is prohibited onsite at all CHI events.

### How to Register: DiscoveryOnTarget.com

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode DOT F when registering!